Form 4: CONMED Corp Executive Pat Beyer Granted Stock Options

Pat Beyer, President Int'l & Global Ortho at CONMED Corp, was granted 44,677 stock options on March 1, 2024, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that Pat Beyer, President Int'l & Global Ortho at CONMED Corp, received 44,677 stock options on March 1, 2024.
• The options were granted under the company's 2018 Long-Term Incentive Plan and vest in equal amounts over a five-year period.
• The exercise price of the options is $79.95.
• A Limited Power of Attorney was executed on September 13, 2023, granting Heather L. Cohen, Lindsey F. Brewer, and Thomas Fistek the authority to act on behalf of Pat Beyer for Section 16 and Rule 144 filings.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options aligns executive compensation with company performance and shareholder value.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the medical technology industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry, similar to companies like Stryker (SYK), Johnson & Johnson (JNJ), and Medtronic (MDT).
• The vesting schedule of five years is also a common practice to ensure long-term commitment from the executive.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to improve company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates